In recent study, the colchicine could reduce the NLRP3 inflammasome activity or its downstream mediators in the cancer related to chronic inflammation diseases such as the hyperlipidemia with atherosclerosis, tobacco use with chronic obstructive pulmonary disease (COPD) and chronic colitis [1, 5, 11–13]. The gene discussed is NLRP3; the disease is Chronic colitis.